#1 Clinical Trials Search in Europe

Alpha-1-Proteinase Inhibitor (Human)

This article examines ongoing clinical trials investigating the use of Alpha-1-Proteinase Inhibitor (Human) in treating pulmonary emphysema associated with Alpha-1 Antitrypsin Deficiency (AATD). These studies aim to evaluate the efficacy and safety of different administration methods and dosages of this therapy for patients with AATD-related lung conditions.

Table of Contents

What is Alpha-1 Proteinase Inhibitor?

Alpha-1 Proteinase Inhibitor (Human), also known as Alpha-1 Antitrypsin or AAT, is a medication used to treat a genetic condition called Alpha-1 Antitrypsin Deficiency[1]. This treatment is derived from human plasma and is designed to supplement the missing or deficient protein in patients with this condition.

What is Alpha-1 Antitrypsin Deficiency?

Alpha-1 Antitrypsin Deficiency (AATD) is a genetic disorder that can lead to serious lung and liver problems. In this condition, the body doesn’t produce enough of a protein called alpha-1 antitrypsin, which protects the lungs from damage. As a result, people with AATD are at higher risk of developing pulmonary emphysema, a condition that makes it difficult to breathe[2].

How Does Alpha-1 Proteinase Inhibitor Work?

Alpha-1 Proteinase Inhibitor works by replacing the missing or deficient protein in patients with AATD. This helps to protect the lungs from ongoing damage caused by enzymes called neutrophil elastase, which can break down lung tissue. By increasing the levels of alpha-1 antitrypsin in the blood and lungs, the treatment aims to slow down the progression of lung damage and preserve lung function[1].

Administration and Dosage

Alpha-1 Proteinase Inhibitor is typically administered through intravenous infusion. The dosage and frequency can vary, but current research is exploring different regimens:

  • Weekly infusions of 60 mg/kg body weight[1]
  • Weekly infusions of 120 mg/kg body weight (being studied)[1]

Additionally, researchers are investigating an inhaled form of the medication:

  • Daily inhalation of 80 mg using a nebulizer[3]

Efficacy and Benefits

Studies are ongoing to determine the full extent of the benefits of Alpha-1 Proteinase Inhibitor. Current research is focusing on several key areas:

  • Slowing lung tissue loss: Measured using CT scans to assess lung density[1]
  • Improving lung function: Assessed through measures like FEV1 (forced expiratory volume in 1 second)[3]
  • Reducing COPD exacerbations: Monitoring the frequency and severity of flare-ups[1]
  • Quality of life: Evaluated using questionnaires like the St. George’s Respiratory Questionnaire[2]

Safety and Side Effects

Alpha-1 Proteinase Inhibitor is generally well-tolerated, but like all medications, it can have side effects. Researchers are closely monitoring the safety profile of the treatment, including:

  • Adverse events and serious adverse events
  • Changes in physical examination findings
  • Alterations in clinical laboratory parameters
  • Development of antibodies against the medication[2]

Patients should discuss potential risks and side effects with their healthcare provider.

Ongoing Research

Several clinical trials are currently underway to further investigate the efficacy and safety of Alpha-1 Proteinase Inhibitor:

  • A study comparing two different dosages (60 mg/kg vs. 120 mg/kg) of intravenous Alpha-1 Proteinase Inhibitor[1]
  • A long-term safety study of weekly intravenous infusions at 60 mg/kg[2]
  • An investigation into an inhaled form of the medication, administered daily at 80 mg[3]

Who is Eligible for Treatment?

Eligibility for Alpha-1 Proteinase Inhibitor treatment typically includes:

  • Confirmed diagnosis of Alpha-1 Antitrypsin Deficiency (specific genotypes like ZZ, SZ, Z(null))
  • Low levels of alpha-1 antitrypsin in the blood (usually <11 μM)
  • Evidence of lung disease, such as emphysema
  • Moderate to severe airflow limitation (typically measured by lung function tests)
  • Age between 18 and 70 years (in most studies)[1][3]

Specific eligibility criteria may vary depending on the treatment protocol or clinical trial.

Conclusion

Alpha-1 Proteinase Inhibitor (Human) represents an important treatment option for individuals with Alpha-1 Antitrypsin Deficiency. While research is ongoing to fully understand its benefits and optimal use, it offers hope for slowing the progression of lung damage in this genetic condition. Patients with AATD should consult with their healthcare providers to determine if this treatment is appropriate for their specific situation.

Aspect Details
Treatment Alpha-1-Proteinase Inhibitor (Human)
Administration Methods Intravenous infusion, Inhalation
Dosages 60 mg/kg/week, 120 mg/kg/week (IV); 80 mg/day (Inhalation)
Target Condition Pulmonary Emphysema due to Alpha-1 Antitrypsin Deficiency
Primary Endpoints Lung density (CT densitometry), FEV1 change
Secondary Endpoints COPD exacerbations, Quality of life measures, Safety assessments
Study Duration 2-4 years (including open-label extensions)
Key Inclusion Criteria Adults with AATD, FEV1 30-80% predicted, No recent severe exacerbations
Key Exclusion Criteria Recent smoking, Severe concomitant diseases, Recent lung surgery

FAQ

  • What is Alpha-1-Proteinase Inhibitor (Human) and how is it used in these trials? Alpha-1-Proteinase Inhibitor (Human) is a protein that helps protect lung tissue. In these trials, it's being tested as a treatment for people with Alpha-1 Antitrypsin Deficiency (AATD) who have developed pulmonary emphysema. It's administered either intravenously or through inhalation to see if it can slow down lung tissue damage.
  • Who are the target patients for these clinical trials? The trials target adult patients with congenital Alpha-1 Antitrypsin Deficiency who have moderate to severe airflow limitation. Specifically, they look for patients with FEV1 (a measure of lung function) between 30% and 80% of predicted values, and without a recent history of frequent severe COPD exacerbations.
  • What are the main objectives of these clinical trials? The main objectives are to assess the efficacy and safety of Alpha-1-Proteinase Inhibitor (Human) in slowing the progression of lung tissue loss, reducing the incidence of severe COPD exacerbations, and improving lung function measures like FEV1. The trials also aim to evaluate long-term safety and the effect on overall disease progression.
  • How long do these clinical trials last? The duration of these trials varies, but they generally last between 2 to 4 years. Some studies have an initial double-blind period of 2 years, followed by an open-label extension period for an additional 2 years, allowing for long-term efficacy and safety assessments.
  • What are some of the key measurements used in these trials? Key measurements include lung density assessed by CT scans, lung function tests like FEV1 (forced expiratory volume in 1 second), frequency and severity of COPD exacerbations, quality of life questionnaires, and various safety parameters including physical examinations and blood tests. Some trials also measure the 6-minute walk test to assess exercise capacity.

Ongoing Clinical Trials on Alpha-1-Proteinase Inhibitor (Human)

  • Study on Long-term Safety of Weekly Intravenous Alpha-1-Proteinase Inhibitor for Patients with Pulmonary Emphysema Due to Alpha-1-Antitrypsin Deficiency

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Estonia Finland France Poland Sweden

  • Study on the Effects of Alpha-1-Proteinase Inhibitor for Patients with Pulmonary Emphysema Due to Alpha-1 Antitrypsin Deficiency

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Finland France Poland Sweden

Glossary

  • Alpha-1 Antitrypsin Deficiency (AATD): A genetic condition where the body doesn't make enough of a protein called alpha-1 antitrypsin, which can lead to lung and liver problems.
  • Pulmonary Emphysema: A lung condition where the air sacs (alveoli) in the lungs are damaged, making it difficult to breathe.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of how much air a person can exhale in one second. It's used to assess lung function.
  • CT Densitometry: A technique using computed tomography (CT) scans to measure the density of lung tissue, which can indicate the progression of emphysema.
  • COPD Exacerbation: A sudden worsening of COPD symptoms, which can be mild, moderate, or severe, often requiring additional treatment.
  • Intravenous (IV): A method of administering medication directly into a vein.
  • Open-Label Extension: A phase of a clinical trial where all participants receive the active treatment, usually following a double-blind phase.
  • Double-Blind Study: A type of clinical trial where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • 6-Minute Walk Test: A test that measures the distance an individual can walk in 6 minutes, used to assess exercise capacity and functional status in people with cardiopulmonary diseases.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-alpha-1-proteinase-inhibitor-for-patients-with-pulmonary-emphysema-due-to-alpha-1-antitrypsin-deficiency/
  2. http://clinicaltrials.eu/trial/study-on-long-term-safety-of-weekly-intravenous-alpha-1-proteinase-inhibitor-for-patients-with-pulmonary-emphysema-due-to-alpha-1-antitrypsin-deficiency/
  3. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-kamada-aat-for-inhalation-in-adults-with-alpha-1-antitrypsin-deficiency-and-moderate-to-severe-breathing-issues/